JPRN-UMIN000006622已完成2 期
Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016) - Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016)
orth East Japan Study Group0 个研究点目标入组 36 人开始时间: 2011年10月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of hemoptysis 2) High risk of bleeding or thrombus events 3) History of anticoagulant within 10 days before enrollment 4) Grade 2 or worse neuropathy 5) Uncontrollable hypertension 6) Symptomatic brain metastasis 7) Uncontrollable pleural effusion or peritoneal effusion 8) Scheduled operation 9) Severe complications 10) Severe infection 11) History of active double cancer 12) No intention to birth control 13) Unstable psychic disorder 14) History of treatment drug 15) History of severe allergic reaction with platinum drug or monoclonal antibody 16) History of allergic reaction with taxan drug, polyoxyethylene or alcohol. 17) Decision of ineligibility by a physician.
研究者
相似试验
招募中
不适用
Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaadvanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumoniaJPRN-UMIN000018322IP lung cancer study group35
已完成
2 期
Phase2 Trial of Carboplatin-Paclitaxel bi-weekly and Bevacizumab combination therapy for Elderly Patients With Nonsquamous Non-Small-Cell Lung Canceronsquamous Non-Small-Cell Lung CancerJPRN-UMIN000006525Shimane University, School of Medicine23
已完成
不适用
Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumoniaJPRN-UMIN000018248IP lung cancer study group40
已完成
2 期
A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancerJPRN-UMIN000001358West Japan Oncology Group40
进行中（未招募）
不适用
A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel induction followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected stage III or IV ovarian carcinoma - NDEUCTR2006-000126-31-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI